MX2018009406A - Conjugados de glucosa de triptolido, analogos y usos de los mismos. - Google Patents
Conjugados de glucosa de triptolido, analogos y usos de los mismos.Info
- Publication number
- MX2018009406A MX2018009406A MX2018009406A MX2018009406A MX2018009406A MX 2018009406 A MX2018009406 A MX 2018009406A MX 2018009406 A MX2018009406 A MX 2018009406A MX 2018009406 A MX2018009406 A MX 2018009406A MX 2018009406 A MX2018009406 A MX 2018009406A
- Authority
- MX
- Mexico
- Prior art keywords
- triptolide
- analogs
- glucose
- compounds
- glucose conjugates
- Prior art date
Links
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 title abstract 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title abstract 2
- 239000008103 glucose Substances 0.000 title abstract 2
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
- C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
- C07J73/003—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by oxygen as hetero atom
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291416P | 2016-02-04 | 2016-02-04 | |
| PCT/US2017/016527 WO2017136739A1 (en) | 2016-02-04 | 2017-02-03 | Glucose conjugates of triptolide, analogs and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018009406A true MX2018009406A (es) | 2018-11-09 |
Family
ID=59500284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018009406A MX2018009406A (es) | 2016-02-04 | 2017-02-03 | Conjugados de glucosa de triptolido, analogos y usos de los mismos. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10695319B2 (enExample) |
| EP (1) | EP3411121B1 (enExample) |
| JP (1) | JP7042744B2 (enExample) |
| CN (1) | CN108601952B (enExample) |
| AU (1) | AU2017214572A1 (enExample) |
| CA (1) | CA3013619A1 (enExample) |
| MX (1) | MX2018009406A (enExample) |
| WO (1) | WO2017136739A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109942665B (zh) * | 2018-04-02 | 2021-04-06 | 欣凯医药化工中间体(上海)有限公司 | 雷公藤内酯醇衍生物及其制备方法和应用 |
| CN109897053B (zh) * | 2019-03-28 | 2020-05-29 | 中国医学科学院医药生物技术研究所 | 雷斯吲哚甲及其制备方法和抗丙型肝炎病毒用途 |
| CN111040018A (zh) * | 2019-12-30 | 2020-04-21 | 广东省中医院(广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院) | 丙烯酸雷公藤甲素酯、其制备方法及其应用 |
| EP4086271B1 (en) | 2019-12-30 | 2023-12-13 | Guangdong Provincial Hospital of TCM | Triptolide acrylate, preparation method therefor and use thereof |
| EP4114468A4 (en) * | 2020-03-02 | 2025-04-09 | The Johns Hopkins University | GLUCOSETRIPTOLIDE CONJUGATES AND USES THEREOF |
| JP2023538424A (ja) * | 2020-08-21 | 2023-09-07 | ルヤン コーポレイション | トリプトリドコンジュゲートおよびその使用 |
| CN115286684A (zh) * | 2022-05-20 | 2022-11-04 | 福建医科大学 | 一种糖与雷公藤内酯醇或其衍生物的缀合物及其制备方法与应用 |
| ES3035530T3 (en) | 2023-03-09 | 2025-09-04 | Minneamrita Therapeutics Llc | Drug combination for the treatment of stomach cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6218367B1 (en) * | 1998-09-15 | 2001-04-17 | Organomed Corporation | Paclitaxel-carbohydrate conjugates: design, synthesis and biological evaluations |
| US6620843B2 (en) | 2001-01-19 | 2003-09-16 | Pharmagenesis | Anticancer treatment using triptolide prodrugs |
| CA2448795A1 (en) | 2001-03-15 | 2002-09-26 | Pharmagenesis, Inc. | Amino acid derivatives of triptolide compounds as immune modulators and anticancer agent |
| US9150600B2 (en) * | 2009-05-07 | 2015-10-06 | Regents Of The University Of Minnesota | Triptolide prodrugs |
-
2017
- 2017-02-03 CN CN201780010159.3A patent/CN108601952B/zh active Active
- 2017-02-03 EP EP17748283.3A patent/EP3411121B1/en active Active
- 2017-02-03 JP JP2018540128A patent/JP7042744B2/ja active Active
- 2017-02-03 AU AU2017214572A patent/AU2017214572A1/en not_active Abandoned
- 2017-02-03 MX MX2018009406A patent/MX2018009406A/es unknown
- 2017-02-03 US US16/074,750 patent/US10695319B2/en active Active
- 2017-02-03 WO PCT/US2017/016527 patent/WO2017136739A1/en not_active Ceased
- 2017-02-03 CA CA3013619A patent/CA3013619A1/en not_active Abandoned
-
2020
- 2020-06-11 US US16/899,226 patent/US20200297693A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019509986A (ja) | 2019-04-11 |
| US20200297693A1 (en) | 2020-09-24 |
| EP3411121A1 (en) | 2018-12-12 |
| CA3013619A1 (en) | 2017-08-10 |
| CN108601952A (zh) | 2018-09-28 |
| CN108601952B (zh) | 2022-03-04 |
| EP3411121A4 (en) | 2019-12-18 |
| EP3411121B1 (en) | 2024-09-11 |
| US10695319B2 (en) | 2020-06-30 |
| AU2017214572A1 (en) | 2018-08-16 |
| JP7042744B2 (ja) | 2022-03-28 |
| WO2017136739A1 (en) | 2017-08-10 |
| US20190038596A1 (en) | 2019-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018009406A (es) | Conjugados de glucosa de triptolido, analogos y usos de los mismos. | |
| WO2014197871A3 (en) | Antibody-drug conjugates, compositions and methods of use | |
| MX340090B (es) | Analogos de spliceostatina. | |
| MY174813A (en) | Cytotoxic and anti-mitotic compounds, and methods of using the same | |
| NZ733055A (en) | Anti-c10orf54 antibodies and uses thereof | |
| MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
| PH12016501966A1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| PH12014501229A1 (en) | Antibody-drug conjugates and related compounds, compositions, and methods | |
| NZ724878A (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| MX2016016666A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
| MX388170B (es) | Polimorfos de selinexor | |
| MY186547A (en) | 4?-fluoro-2?-methyl substituted nucleoside derivatives | |
| MX2015002482A (es) | Composicion inmunogenica. | |
| MX376782B (es) | Métodos de administración de composiciones de amantadina. | |
| MX2020002802A (es) | Anticuerpos de cadena pesada que se unen a ectoenzimas. | |
| MX375438B (es) | Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2). | |
| ZA201803476B (en) | Anti-cd22 antibody-maytansine conjugates and methods of use thereof | |
| MX2016002217A (es) | Compuestos con actividad pesticida. | |
| MX2020009966A (es) | Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina. | |
| MX368268B (es) | Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih). | |
| MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
| MX2018004696A (es) | Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos. | |
| PH12018500014A1 (en) | Total synthesis of shishijimicin a and analogs thereof | |
| PH12017501147A1 (en) | Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs |